Overview

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

Status:
Withdrawn
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of Ixazomib when combined with Pomalidomide and Dexamethasone, in terms of overall response rate in subjects with relapsed Multiple Myeloma
Phase:
Phase 2
Details
Lead Sponsor:
University of Arkansas
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Glycine
Ixazomib
Pomalidomide
Thalidomide